The European Federation of Pharmaceutical Industries and Associations (EFPIA) has announced the launch of IMI2, with a budget of €3.3 billion (US$ 4.5 bn).
The European Federation of Pharmaceutical Industries and Associations (EFPIA) has announced the launch of IMI2, with a budget of €3.3 billion (US$ 4.5 bn).
IMI (the Innovative Medicines Initiative) is a public-private partnership (PPP) between the European Commission and EFPIA, and was already the largest healthcare PPP in Europe. The budget for its first phase (2008-2013) was €2 bn (US$2.7 bn).
So far, IMI projects have shown a positive impact on research and development: the NEWMEDS project has created the largest known database of studies on schizophrenia; the New Drugs for Bad Bugs Programme has launched project to tackle the growing threat of anti-microbial resistance; and the eTox project is developing a drug safety database based on both industry and public toxicology data, in a step towards greater safety for patients.
The
IMI2 Strategic Research Agendawas developed to address areas of unmet medical need, finding inspiration in the World Health Organization’s Priority Medicines Report. Projects aim to advance trends in personalized medicines; to further R&D in areas of unmet medical need; and to address the regulatory context in hopes of speeding translation from research to innovation.
Ruxandra Draghia-Akli, Director, Health, DG Research and Innovation, European Commission:, said “IMI2 will carry on the collaborative spirit of IMI by bringing together the pharmaceutical industry, academic health research partners, small and medium enterprises, patients and regulators to advance scientific research and development for a healthy European society.”
More information on IMI 2 can be found here.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
MDMA Therapy for Mental Health Conditions: Do the Benefits Outweigh the Risks?
October 25th 2024Despite a recent FDA Complete Response Letter issued to Lykos for midomafetamine capsules for the treatment of post-traumatic stress disorder, experts believe that the future is bright for psychedelic drugs that treat mental health conditions.
The Transformative Role of Medical Information in Customer Engagement
October 3rd 2024Stacey Fung, Head of Global Medical Information at Gilead Lifesciences, delves into the evolving role of Medical Information (MI) in the pharmaceutical industry. Covering key topics like patient engagement through omnichannel strategies, combating misinformation, and leveraging AI to enhance medical inquiries, the conversation with Stacey highlights MI's critical role in ensuring patient safety and supporting drug development. She also shares her professional journey and tidbits for early career professionals on professional development.
The Impact of Artificial Intelligence on the Creation of Medicines
October 24th 2024Najat Khan, chief R&D officer, chief commercial officer, Recursion, and Fred Hassan, director, Warburg Pincus, discuss how artificial intelligence can help reduce healthcare costs at the 20th Annual Young & Partners Pharmaceutical Executive Summit held at the Yale Club of New York.